Eric Cantor Appointed President of PhRMA
Eric Cantor has been named the new president of PhRMA, the primary trade organization for the U.S. pharmaceutical industry.
Baltimore, MD, September 29, 2026 — Eric Cantor has been appointed as the new president of the Pharmaceutical Research and Manufacturers of America (PhRMA), the primary trade organization representing the U.S. pharmaceutical industry. The announcement marks a significant leadership change for the influential industry group.
PhRMA serves as a key voice for pharmaceutical and biotechnology companies in the United States. The organization advocates for policies that foster innovation, support the development of new medicines, and ensure patient access to treatments. Its membership comprises many of the leading biopharmaceutical companies operating in the country.
The role of president is central to steering the organization’s strategic direction, managing its public affairs, and engaging with policymakers, stakeholders, and the public. The appointment of a new president often signifies an evolution in the organization’s priorities and approach to addressing industry challenges and opportunities.
Details regarding the specific responsibilities Cantor will undertake, the timeline for his assumption of duties, or any immediate strategic shifts planned for PhRMA were not provided in the summary. The summary did not include information on the selection process, the duration of his term, or whether he will be involved in specific ongoing legislative or regulatory initiatives.
Eric Cantor’s background and prior experience are relevant to his new position. He previously served in the U.S. House of Representatives, representing Virginia’s 7th congressional district, and held leadership positions including House Majority Leader. His tenure in Congress involved extensive work on economic policy, healthcare, and other legislative matters that intersect with the biopharmaceutical sector.
PhRMA’s activities encompass a wide range of issues, including drug pricing, research and development incentives, intellectual property protection, and regulatory affairs. The organization plays a critical role in shaping the landscape for pharmaceutical innovation and access in the United States.
Story summarized from the original created by Nathaniel Weixel,Joseph Choi on thehill.com, see more information here.
Media gallery
